# BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

> **NCT04018248** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 26 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
- B Cell Lymphoma
- Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia
- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** BR101801 (Phase Ia)
- **DRUG:** BR101801 (Phase Ib)

## Key facts

- **NCT ID:** NCT04018248
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-21
- **Primary completion:** 2023-09-21
- **Final completion:** 2023-09-21
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04018248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04018248, "BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04018248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*